Extended Data Fig. 3: Serum antibody levels against SARS-CoV-2.
From: SARS-CoV-2 evolution during treatment of chronic infection
a, Anti-SARS-CoV-2 IgG antibodies in patient X1, before and after convalescent plasma treatment (days 66 and 95) compared with RNA+ patients with COVID-19 and pre-pandemic healthy control individuals. Red, grey and gold, IgG antibodies against the nucleocapsid (N) protein, trimeric spike (S) protein and RBD of SARS-CoV-2 were measured by multiplexed particle-based flow cytometry (Luminex) in RNA+ patients with COVID-19 (n = 20, red dots), pre-pandemic healthy control individuals (n = 20, grey dots) and convalescent donor plasma (orange dots). Patient sera over time are shown in blue: anti-SARS-CoV-2 IgG to nucleocapsid (blue squares), spike (blue circles) and RBD (blue triangles). Data are mean fluorescent intensity (MFI) ± s.d. The timing of convalescent plasma units (days after first positive test) is also shown. b, SARS-CoV-2 antibody titres in convalescent plasma. Measurement of SARS-CoV-2-specific IgG antibody titres in three units of convalescent plasma by Euroimmun assay. OD, optical density.
